Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis
Controlled Studies in This CER: Adding Biologic DMARDs to JIA Treatment (1 of 2)
There are few studies of biologic DMARDs in children with JIA, and the numbers of treated and control group patients are limited. Methotrexate or other nonbiologic DMARDs—along with NSAIDs, oral corticosteroids, and analgesics—were permitted in the comparison group in most studies.
One study of abatacept included 5 patients with persistent oligoarticular disease, 43 with extended oligoarticular disease, 205 with polyarticular disease, and 60 with systemic disease. One study of adalimumab included 171 patients with polyarticular disease. One study of anakinra included 33 patients with polyarticular disease, 6 with pauciarticular disease, and 11 with systemic disease. One study of tocilizumab included 43 patients with undefined JIA.
Keywords: juvenile idiopathic arthritis | JIA | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | TNF-alpha blockers | biologic DMARD | nonbiologic DMARD | non-biologic DMARD | anti-inflammatory | polyarticular | pauciarticular | oligoarticular | systemic onset | abatacept | adalimumab | anakinra | tocilizumab | corticosteroids | methotrexate
- Kemper A, Coeytaux R, Sanders G, et al. Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA). Comparative Effectiveness Review No. 28 (Prepared by the Duke Evidence-based Practice Center under Contract No. HHSA 290-2007-10066-I). Rockville, MD: Agency for Healthcare Research and Quality; September 2011. AHRQ Publication No. 11-EHC039-EF. Available at www.effectivehealthcare.ahrq.gov/dmardsjia.cfm.
Your slide tray is being processed.